GLP-1 / Ozempic Off-Label Use & Availability

**SHORT SYNTHESIS**

Social media discussion of GLP-1 off-label use centers on two main tensions: supply scarcity versus accessibility, and the role of compounding pharmacies in filling gaps left by pharmaceutical shortages.

On TikTok, the dominant framing emphasizes contradiction—users note that while semaglutide is marketed as "affordable and accessible," global shortages create waitlists that prevent people who medically need the drug from obtaining it. One TikTok post (170 engagement) frames FDA restrictions on compounding pharmacies as having backfired, flooding the market with alternatives while leaving legitimate patients without access. Another post positions semaglutide as paradoxically more available than mental health care, highlighting systemic healthcare inequity.

Reddit discussion is fragmented and low-engagement, consisting mostly of academic recruitment posts seeking intimate partners of GLP-1 users, personal anecdotes about starting the drug, and one report of a potential adverse reaction (angioedema). X posts from accounts focused on peptides show modest engagement but no substantive debate visible in the data.

The gap between social media chatter and mainstream coverage is notable: users are actively discussing supply chain dynamics, regulatory trade-offs, and access disparities, but these conversations appear confined to niche communities with minimal mainstream media engagement on the topic.